This phase 2 trial met its primary endpoint, showing anti-tumor activity of pertuzumab plus trastuzumab with a confirmed objective response rate (ORR) of 30% and 28% in patients with mCRC harboring HER2 amplification prospectively confirmed by tumor tissue or ctDNA analysis, respectively. Here, ERBB2 is linked to neoplasm.